ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstracts tagged "adalimumab and ankylosing spondylitis (AS)"

  • Abstract Number: 2622 • 2018 ACR/ARHP Annual Meeting

    Regional and Temporal Variation in the Baseline Profile of Ankylosing Spondylitis Patients Initiating Adalimumab Following Failure of Non-Biologic Treatment in Canadian Routine Care

    Louis Bessette1,2, Majed Khraishi3, Viktoria Pavlova4, Brandusa Florica5,6 and Valencia P. Remple7,8, 1Centre Hospitalier de l'Université Laval, Quebec, QC, Canada, 2Rheumatology, Laval University, Quebec, QC, Canada, 3Memorial University of Newfoundland, St. John's, NF, Canada, 4McMaster University, Hamilton, ON, Canada, 5Trillium Health Partners, Mississauga, ON, Canada, 6University of Toronto, Toronto, ON, Canada, 7School of Population and Public Health, University of British Columbia, Vancouver, BC, Canada, 8AbbVie Corporation, Montreal, QC, Canada

    Background/Purpose: Treatment selection in Canadian routine clinical care is based on the judgment of the treating physician but is also affected by treatment guidelines and…
  • Abstract Number: 2847 • 2015 ACR/ARHP Annual Meeting

    Predictors of Therapeutic Response in Ankylosing Spondylitis Patients Initiating Therapy with Adalimumab in a German Non-Interventional Study 

    Michaela Koehm1,2, Frank Behrens1,3, Eva C. Scharbatke4, Marc Schmalzing5, Holger Gnann6, Gerd Greger7, Bianca Wittig8, Hans Peter Tony9 and Harald Burkhardt3,10, 1Clinical Research, Fraunhofer Institute for Molecular Biology and Applied Ecology IME, Project Group Translational Medicine & Pharmacology TMP, Frankfurt/Main, Germany, 2Rheumatology, Goethe-University Frankfurt, Frankfurt/Main, Germany, 3Rheumatology, Goethe-University Frankfurt, Frankfurt, Germany, 4Rheumatology/Immunology, University of Würzburg, Würzburg, Germany, 5Rheumatology/Immunology, University Würzburg, Würzburg, Germany, 6Abteilung Biostatistik, GKM Gesellschaft für Therapieforschung mbH, München, Germany, 7AbbVie Deutschland GmbH & Co.KG, Wiesbaden, Germany, 8Abbott GmbH & Co KG, Wiesbaden, Germany, 9Rheumatology / Clinical Immunology, University Hospital Würzburg, Würzburg, Germany, 10Fraunhofer Institute for Molecular Biology and Applied Ecology IME, Project Group Translational Medicine & Pharmacology TMP, Frankfurt/Main, Germany

    Background/Purpose: Ankylosing spondylitis (AS) is associated with a significant burden of illness and has limited treatment options. The identification of predictors of response to anti-tumor necrosis…
  • Abstract Number: 1509 • 2013 ACR/ARHP Annual Meeting

    Immunogenicity, Adalimumab Levels and Clinical Response In Ankylosing Spondylitis Patients During 24 Weeks Of Follow-Up

    Eva L. Kneepkens1, James C. Wei2, Michael T. Nurmohamed3,4, Kai-Jieh Yeo5, CY Chen6, Irene E. van der Horst-Bruinsma1,7, Desiree van der Kleij8, Theo Rispens9, Gertjan Wolbink3,9 and Charlotte L. M. Krieckaert3, 1Jan van Breemen Research Institute | Reade, Amsterdam, Netherlands, 2Allergy/Immunology/Rheumatolog, Chung Shan Med Univ Hospital, Taichung, Taiwan, 3Rheumatology, Jan van Breemen Research Institute | Reade, Amsterdam, Netherlands, 4Rheumatology, VU University medical centre, Amsterdam, Netherlands, 5Division of Allergy, Immunology and Rheumatology, Chung Shan Med Univ Hospital, Taichung, Taiwan, 6Chung Shan Med Univ Hospital, Taichung, Taiwan, 7Department of Rheumatology, VU University Medical Center, Amsterdam, Netherlands, 8Sanquin Diagnostic Services, Amsterdam, Netherlands, 9Sanquin Research, Amsterdam, Netherlands

    Background/Purpose: Immunogenicity influences adalimumab levels and therefore clinical response in patients with rheumatic diseases. Objectives: To study the relation between clinical response, adalimumab levels and…
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
This site uses cookies: Find out more.